Development of L-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity

被引:13
作者
Song, YL
Roller, PP
Long, YQ
机构
[1] CAS, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[2] NCI, Med Chem Lab, NIH, Frederick, MD 21702 USA
关键词
aminotyrosine; Grb2-SH2; domain; nonphosphorylated ligand; cyclic peptide; sulfoxide; SPR assay;
D O I
10.1016/j.bmcl.2004.03.103
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Synthesis of orthogonally protected (2S)-2-amino-3-(3 -amino-4-hydroxy-phenyl)-propionic acid (10) suitable for solid phase peptide synthesis and its first use for the preparation of nonphosphorylated Grb2-SH2 domain antagonists (4a-c) are reported. The 3-aminotyrosine containing sulfoxide-cyclized hexapeptide (4b) exhibited potent Grb2-SH2 domain binding affinity with IC50 = 50 nM which represents the highest affinity yet reported for a peptide inhibitor against Grb2-SH2 domain with only six residues free of phosphotyrosine or phosphotyrosine mimics. This potent small peptidomimetic 4b may be representative of a new class of therapeutically relevant Grb2-SH2 domain-directed agents, and acts as a chemotherapeutic lead for the treatment of erbB2-related cancers. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3205 / 3208
页数:4
相关论文
共 28 条
[1]   PREPARATION AND APPLICATION OF THE 5-(4-(9-FLUORENYLMETHYLOXYCARBONYL)AMINOMETHYL-3,5-DIMETHOXYPHENOXY)VALERIC ACID (PAL) HANDLE FOR THE SOLID-PHASE SYNTHESIS OF C-TERMINAL PEPTIDE AMIDES UNDER MILD CONDITIONS [J].
ALBERICIO, F ;
KNEIBCORDONIER, N ;
BIANCALANA, S ;
GERA, L ;
MASADA, RI ;
HUDSON, D ;
BARANY, G .
JOURNAL OF ORGANIC CHEMISTRY, 1990, 55 (12) :3730-3743
[2]  
ATHERTON E, 1989, PRACTICAL APPROACH
[3]   A COMPARISON OF ACID LABILE LINKAGE AGENTS FOR THE SYNTHESIS OF PEPTIDE C-TERMINAL AMIDES [J].
BERNATOWICZ, MS ;
DANIELS, SB ;
KOSTER, H .
TETRAHEDRON LETTERS, 1989, 30 (35) :4645-4648
[4]   Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase [J].
Bradshaw, JM ;
Mitaxov, V ;
Waksman, G .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :971-985
[5]  
Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161
[6]   High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia [J].
Feller, SM ;
Tuchscherer, G ;
Voss, J .
LEUKEMIA & LYMPHOMA, 2003, 44 (03) :411-427
[7]   Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways [J].
Fretz, H ;
Furet, P ;
García-Echeverría, C ;
Rahuel, J ;
Schoepfer, J .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (18) :1777-1796
[8]  
Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO
[9]  
2-B
[10]   Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity [J].
Li, P ;
Zhang, MC ;
Peach, ML ;
Zhang, XD ;
Liu, HP ;
Nicklaus, M ;
Yang, DJ ;
Roller, PP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 307 (04) :1038-1044